Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498011 | 0.87 | ELANE (0.63) | ELANECTRB1PTGDRPPARGPPARA | |
| SCHEMBL6505687 | 0.82 | ELANE (0.49) | ELANECTRB1PTGDRPPARGPPARA | |
| SCHEMBL7838428 | 0.81 | ELANE (0.61) | ELANECTRB1 | |
| SCHEMBL6496223 | 0.78 | ELANE (0.72) | ELANECTRB1PTPN1APP | |
| SCHEMBL6499066 | 0.78 | ELANE (0.64) | ELANECTRB1PTPN1APPITGB3 | |
| SCHEMBL6497584 | 0.78 | ELANE (0.62) | ELANECTRB1PTGDR | |
| SCHEMBL6503996 | 0.77 | ELANE (0.60) | ELANECTRB1LCKAPPITGA4 | |
| SCHEMBL6505020 | 0.77 | ELANE (0.59) | ELANECTRB1LCKAPPITGA4 | |
| SCHEMBL6498805 | 0.76 | ELANE (0.46) | ELANECTRB1PTGDRPPARGPPARA | |
| SCHEMBL6498606 | 0.76 | ELANE (0.59) | ELANECTRB1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | ELANE 1199/4885CTRB1 1716/4885PTGDR 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.